Thomas Strüngmann
Thomas Strüngmann (born 1950) founded generic drug maker ($1.6 billion sales during 2004) in 1986. In 2005, he and his brother Andreas sold Hexal for $6.7B.[1] They earned $8B on their stake in BioNTech SE, the German company developing the Pfizer vaccine.[2] They own approximately 50% of the company as well as significant ownership in 4SC and Immatics.[3] He currently has the largest health-care earned fortune with his brother. [4]
The brothers operate out of a family office, Athos Service. [1]
See also[]
- List of billionaires
References[]
- ^ Jump up to: a b Manskar, Noah (2020-11-13). "COVID-19 vaccine hopes have made these twins $8 billion richer". New York Post. Retrieved 2021-07-13.
- ^ Stupples, Benjamin (November 13, 2020). "Brothers Build $22 Billion Fortune on Hope for Covid-19 Vaccine". Bloomberg.
- ^ Manskar, Noah (2020-11-13). "COVID-19 vaccine hopes have made these twins $8 billion richer". New York Post. Retrieved 2021-07-13.
- ^ "Bloomberg Billionaires Index". Bloomberg.
External links[]
| hide Authority control  | |
|---|---|
| General |
|
| National libraries | |
| Other | |
 | This German business-related biographical article is a stub. You can help Wikipedia by . |
Categories:
- 1950 births
- Living people
- German billionaires
- 20th-century German businesspeople
- 21st-century German businesspeople
- German business biography stubs